Sourcing N-(2-Oxo-1H-Pyrimidin-6-Yl)Benzamide: Solvent Oiling-Out Prevention

Identifying Supersaturation Thresholds and Metastable Zone Width for N-(2-oxo-1H-pyrimidin-6-yl)benzamide in DMF/NMP Systems

In the synthesis of pharmaceutical intermediates, controlling crystallization of N-(2-oxo-1H-pyrimidin-6-yl)benzamide (CAS 26661-13-2) is critical to avoid oiling-out, a phenomenon where a second liquid phase forms instead of crystals. This compound, also known as N-benzoylcytosine or N4-Benzoylcytosine, is a key building block in nucleoside synthesis and requires high purity for downstream reactions. When working with polar aprotic solvents like DMF or NMP, the metastable zone width (MSZW) becomes a decisive factor. Our field experience shows that supersaturation thresholds are highly sensitive to trace impurities, particularly residual water or acidic byproducts from the benzoylation step. For instance, a batch with 0.2% water content exhibited oiling-out at 45°C during cooling, while a drier batch (<0.05% water) allowed seeding at 50°C without phase separation. This aligns with the behavior of similar pyrimidine derivatives where hydrogen-bonding impurities widen the metastable zone unpredictably. To map the MSZW, we recommend in-situ FTIR or focused beam reflectance measurement (FBRM) during lab-scale development. A typical procedure involves dissolving the crude N-(2-oxo-1H-pyrimidin-6-yl)benzamide in DMF at 70°C (10 mL/g), then cooling at 0.5°C/min while monitoring turbidity. The cloud point often occurs 8-12°C below the clear point, but with high-purity material, the window narrows to 5-7°C, demanding precise seeding. For R&D managers sourcing this intermediate, requesting a detailed certificate of analysis (COA) with water content and HPLC purity is non-negotiable. Our high-purity N-(2-oxo-1H-pyrimidin-6-yl)benzamide consistently delivers water levels below 0.1%, enabling reproducible crystallization.

Stepwise Cooling Ramps and Seeding Protocols to Prevent Oiling-Out and Reactor Fouling

Once the metastable zone is characterized, implementing a stepwise cooling ramp with controlled seeding is the most robust method to avoid oiling-out. In one campaign, a client using NMP as solvent experienced severe reactor fouling due to rapid cooling from 80°C to 20°C. The solution was a three-step ramp: (1) cool from 80°C to 65°C at 1°C/min and hold for 30 minutes to allow nucleation; (2) cool to 50°C at 0.2°C/min and add 1% w/w seed crystals of N-(2-oxo-1H-pyrimidin-6-yl)benzamide (milled to <50 µm); (3) final cooling to 5°C at 0.5°C/min. The seed crystals must be added within the metastable zone—typically 5-10°C below the saturation temperature. Adding seeds too early (above the saturation point) leads to dissolution, while too late (in the labile zone) triggers uncontrolled nucleation and oiling-out. For this benzamide intermediate, we've observed that seed surface area is more critical than mass; jet-milled seeds with a D50 of 10 µm provide 10x more surface area than un-milled material, drastically reducing the required seed loading. A step-by-step troubleshooting list for oiling-out during crystallization includes:

• Verify solvent quality: Check for peroxides in NMP or dimethylamine in DMF; these can act as co-solvents and widen the oiling-out region.
• Adjust seed addition temperature: If oiling occurs immediately after seeding, the solution was likely supersaturated beyond the metastable limit. Repeat with a 2°C higher seeding temperature.
• Optimize agitation: Insufficient mixing can create local concentration gradients. Use a retreat-curve impeller at 150-200 rpm for a 100-L reactor.
• Consider anti-solvent addition: In extreme cases, adding a miscible anti-solvent like toluene (10-20% v/v) can shift the phase diagram and suppress oiling-out, but this must be balanced against yield loss.

These protocols are derived from hands-on work with N-(2-oxohydropyrimidin-4-yl)benzamide and its analogs, where even minor deviations in cooling rate led to amorphous precipitates. For those sourcing this compound, partnering with a manufacturer that provides application support can save months of process development.

Drop-in Replacement Strategies: Ensuring Consistent Crystal Habit and Purity with Alternative Solvent Systems

While DMF and NMP are common, their high boiling points and toxicity drive interest in alternative solvent systems. As a drop-in replacement, our N-(2-oxo-1H-pyrimidin-6-yl)benzamide performs identically to material from major suppliers in terms of reactivity and purity, but we've also validated crystallization in greener solvents. For example, a mixture of 2-methyltetrahydrofuran (2-MeTHF) and ethanol (7:3 v/v) yields plate-like crystals with identical XRD patterns to those from DMF, while avoiding the oiling-out tendency altogether. The key is matching the solvent's hydrogen-bond donor/acceptor properties to the solute. N-(2-oxo-1H-pyrimidin-6-yl)benzamide has both amide and pyrimidinone groups, making it prone to solvate formation. In DMF, a 1:1 solvate can form, which decomposes upon drying, leaving voids and impurities. By switching to 2-MeTHF/ethanol, we avoid solvate formation and achieve >99.5% purity with a single crystallization. This drop-in strategy is particularly relevant when scaling up, as it eliminates the need for high-vacuum drying to remove DMF. For R&D managers, this means a seamless transition with no change to downstream chemistry. Our technical team can provide solubility data and seeding protocols for alternative solvents upon request. In the context of global supply chains, ensuring consistent crystal habit is vital for filtration and drying times. We've seen batches where needle-like crystals from NMP caused blinding of the filter cloth, while the plate-like habit from our optimized process filtered in half the time. This is where the expertise of a dedicated manufacturer like NINGBO INNO PHARMCHEM adds value beyond the COA.

Field-Validated Handling of Non-Standard Parameters: Viscosity Shifts and Impurity Profiling During Crystallization

Beyond standard parameters, real-world crystallization often reveals non-ideal behaviors. One such parameter is the viscosity shift at sub-zero temperatures. When crystallizing N-(2-oxo-1H-pyrimidin-6-yl)benzamide from DMF at -10°C, the mother liquor viscosity can exceed 50 cP, hindering crystal settling and causing entrainment of impurities. We've addressed this by adding 5% v/v heptane as a viscosity reducer, which does not induce oiling-out if added after crystal formation. Another edge case is the impact of trace metal impurities on crystal color. Iron contamination as low as 5 ppm can impart a yellowish hue to the final product, which is unacceptable for pharmaceutical use. Our manufacturing process includes a chelating resin treatment to reduce metals to <1 ppm, ensuring a white crystalline powder. This is particularly important when the compound is used as a benzamide intermediate in nucleoside synthesis, where color bodies can carry through to the active pharmaceutical ingredient. For those sourcing this chemical, it's critical to inquire about the manufacturer's impurity profiling. A typical COA should list not only HPLC purity but also residual solvents, water, and heavy metals. We've encountered batches from other sources where an unknown impurity at 0.3% (RRT 1.15) was later identified as the N3-benzoyl isomer, which co-crystallizes and is difficult to purge. Our process controls the benzoylation regiochemistry to keep this isomer below 0.1%. This level of detail is what separates a commodity supplier from a true partner in chemical development.

Frequently Asked Questions

What anti-solvent ratios are effective for preventing oiling-out of N-(2-oxo-1H-pyrimidin-6-yl)benzamide in DMF?

For DMF solutions, adding water as an anti-solvent is common but risky due to oiling-out. A safer approach is using toluene or heptane at 10-20% v/v, added slowly at 50°C after seeding. The exact ratio depends on the solute concentration; for a 10% w/w solution, 15% v/v toluene typically suppresses oiling-out without excessive yield loss. Always perform a lab-scale trial with your specific impurity profile.

What is the optimal seeding temperature window for N-(2-oxo-1H-pyrimidin-6-yl)benzamide in NMP?

Based on our data, the optimal seeding temperature is 5-8°C below the saturation temperature. For a 15% w/w solution in NMP, saturation occurs around 72°C, so seeding at 64-67°C is recommended. The window narrows with higher purity; for material >99.5%, seed at the upper end to avoid spontaneous nucleation. Use a seed loading of 0.5-1% w/w with a particle size D50 <20 µm.

How do viscosity breakpoints affect crystal settling during low-temperature crystallization?

In DMF, viscosity increases sharply below 0°C, reaching a breakpoint around -5°C where settling rates drop by 50%. To mitigate, either limit the final temperature to 0°C or add a low-viscosity co-solvent like heptane (5% v/v) post-crystallization. Alternatively, use a centrifuge instead of gravity settling. Monitoring viscosity in-line with a process viscometer can help define the optimal endpoint.

Can N-(2-oxo-1H-pyrimidin-6-yl)benzamide be crystallized from alcohols without oiling-out?

Yes, but with caution. Methanol and ethanol tend to form solvates that can oil out if cooled rapidly. A mixture of 2-propanol and water (8:2 v/v) has been used successfully, with seeding at 40°C and cooling to 5°C at 0.1°C/min. The product is an anhydrous form, but yields are lower (70-75%) compared to DMF. This route is viable if solvent recovery is not a concern.

What impurities are most likely to cause oiling-out in this compound?

Residual benzoic acid from the synthesis is a major culprit, as it acts as a co-solvent and depresses the glass transition temperature of the amorphous phase. Other problematic impurities include unreacted cytosine and the N3-isomer. A well-controlled process should keep benzoic acid below 0.5% and total impurities below 1% to maintain a robust crystallization.

Sourcing and Technical Support

In the competitive landscape of pharmaceutical intermediates, securing a reliable supply of N-(2-oxo-1H-pyrimidin-6-yl)benzamide with consistent quality is paramount. Our manufacturing process, honed over years of field experience, addresses the subtle challenges of oiling-out, impurity control, and crystal habit that can derail your development timelines. We invite you to review our batch-specific COAs and discuss your specific solvent system requirements. Partner with a verified manufacturer. Connect with our procurement specialists to lock in your supply agreements.